These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26832191)

  • 1. Free Speech and Pharmaceutical Regulation -- Fishy Business.
    Kapczynski A
    JAMA Intern Med; 2016 Mar; 176(3):295-6. PubMed ID: 26832191
    [No Abstract]   [Full Text] [Related]  

  • 2. The Promotion of Medical Products in the 21st Century: Off-label Marketing and First Amendment Concerns.
    Sharfstein JM; Charo A
    JAMA; 2015 Nov; 314(17):1795-6. PubMed ID: 26367520
    [No Abstract]   [Full Text] [Related]  

  • 3. An Uninformative Truth: The Logic of Amarin's Off-Label Promotion.
    Hey SP; Kesselheim AS
    PLoS Med; 2016 Mar; 13(3):e1001978. PubMed ID: 26978686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maine law requires drug companies to provide clinical trial data.
    Appell D
    J Natl Cancer Inst; 2005 Sep; 97(17):1246. PubMed ID: 16145043
    [No Abstract]   [Full Text] [Related]  

  • 5. The strange allure of state "right-to-try" laws.
    Zettler PJ; Greely HT
    JAMA Intern Med; 2014 Dec; 174(12):1885-6. PubMed ID: 25264589
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmaceuticals and Medical Devices: Business Practices.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2015 Dec; ():1-37. PubMed ID: 27116796
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmaceuticals and medical devices: FDA oversight.
    ; Berry MD
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-86. PubMed ID: 22403845
    [No Abstract]   [Full Text] [Related]  

  • 8. Off-label promotion.
    Somberg J
    Am J Ther; 2006; 13(5):387. PubMed ID: 16988530
    [No Abstract]   [Full Text] [Related]  

  • 9. The future of off-label marketing regulations in the post-Sorrell era.
    Iraggi J
    Seton Hall Law Rev; 2013; 43(3):1137-63. PubMed ID: 23802338
    [No Abstract]   [Full Text] [Related]  

  • 10. PLIVA v. Mensing: generic consumers' unfortunate hand.
    Lee SB
    Yale J Health Policy Law Ethics; 2012; 12(2):209-63. PubMed ID: 23175916
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-31. PubMed ID: 20217914
    [No Abstract]   [Full Text] [Related]  

  • 12. Recent developments help the defense of drug companies in 10b-5 cases.
    Salpeter AN; Hutchins H
    Food Drug Law J; 1996; 51(3):345-53. PubMed ID: 11797711
    [No Abstract]   [Full Text] [Related]  

  • 13. Disagreements Within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015.
    MacGregor A; Zhang AD; Wallach JD; Ross JS; Herder M
    JAMA Netw Open; 2020 Jul; 3(7):e209498. PubMed ID: 32706379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.
    Ochs A
    Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical trial transparency--antidote to weaker off-label-promotion rules?
    Outterson K
    N Engl J Med; 2014 Jul; 371(1):1-3. PubMed ID: 24988551
    [No Abstract]   [Full Text] [Related]  

  • 16. The limits of free speech.
    Nature; 2012 Dec; 492(7429):311. PubMed ID: 23281497
    [No Abstract]   [Full Text] [Related]  

  • 17. Looking for a miracle.
    Marchant J
    New Sci; 2000 Jun; 166(2244):16-7. PubMed ID: 11902203
    [No Abstract]   [Full Text] [Related]  

  • 18. Notification vs approval.
    Novack GD
    Ocul Surf; 2007 Jul; 5(3):255-8. PubMed ID: 17660899
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 20. Bias at the gate?: The pharmaceutical industry's influence on the federally approved drug compendia.
    Gabrielsen L
    Am J Law Med; 2014; 40(1):141-63. PubMed ID: 24844045
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.